Skip to main content
Mitobridge purchased by Astellas for $450M
12/4/2017

Mitochondrial disorder firm Mitobridge was purchased by Astellas Pharma in an amended 2013 deal for $225 million upfront and up to another $225 million in milestones. Mitobridge has an ongoing early-stage study of MA-0211 for patients with Duchenne muscular dystrophy and a preclinical program for mitochondrial myopathies and fatty acid oxidation disorders.

Full Story: